{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-025064","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.015424+00:00","generated_at":"2026-06-02T05:12:32.529620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025","bullets":["Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.","R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.","Cash $17.8M; expects funding operations into second half 2025.","Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.","Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-025064","json":"https://secwatch.observer/filing/0001140361-24-025064.json","markdown":"https://secwatch.observer/filing/0001140361-24-025064.md","text":"https://secwatch.observer/filing/0001140361-24-025064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/0001140361-24-025064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/ef20028745_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:12:32.529620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9df4520fd315240f050d74758352c58006fff549","claim":"FEMASYS INC reported first quarter ended March 31, 2024 results: revenue $271,140, net income $3,599,510, EPS $0.17.","evidence_excerpt":"Quarter Ended March 31, 2024 • Research and development expenses increased by $233,292 to $1,770,731 in Q1 of 2024 from $1,537,439 in Q1 of 2023 • Sales decreased by $22,844 to $271,140 in Q1 of 2024 from $293,984 in Q1 of 2023 • Net loss was $3,599,510 or $0.17 per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2024,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/0001140361-24-025064-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$271,140"},{"label":"Net income","value":"$3,599,510"},{"label":"EPS","value":"$0.17"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}